AtriCure Inc. (NASDAQ:ATRC) COO Douglas J. Seith Sells 48,804 Shares

AtriCure Inc. (NASDAQ:ATRC) COO Douglas J. Seith sold 48,804 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.63, for a total value of $1,250,846.52. Following the sale, the chief operating officer now owns 208,281 shares of the company’s stock, valued at $5,338,242.03. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of ATRC stock traded up $0.80 on Friday, reaching $26.02. The stock had a trading volume of 177,634 shares, compared to its average volume of 241,345. The stock has a market cap of $1.01 billion, a P/E ratio of -27.68 and a beta of 0.30. AtriCure Inc. has a 1 year low of $22.57 and a 1 year high of $34.39. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.10 and a current ratio of 3.72. The company has a 50 day simple moving average of $25.54 and a 200 day simple moving average of $28.57.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.01. The firm had revenue of $58.90 million for the quarter, compared to the consensus estimate of $57.76 million. AtriCure had a negative return on equity of 13.06% and a negative net margin of 9.46%. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period last year, the business posted ($0.19) EPS. On average, equities research analysts anticipate that AtriCure Inc. will post -0.94 earnings per share for the current fiscal year.

Several brokerages recently weighed in on ATRC. Needham & Company LLC set a $39.00 target price on AtriCure and gave the company a “buy” rating in a report on Monday, August 12th. Piper Jaffray Companies set a $40.00 price target on AtriCure and gave the company a “buy” rating in a research report on Monday, August 12th. ValuEngine lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 19th. JPMorgan Chase & Co. restated a “buy” rating on shares of AtriCure in a research note on Friday, September 6th. Finally, Zacks Investment Research downgraded AtriCure from a “hold” rating to a “sell” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $36.00.

Large investors have recently bought and sold shares of the business. Assetmark Inc. increased its holdings in shares of AtriCure by 109.7% in the second quarter. Assetmark Inc. now owns 975 shares of the medical device company’s stock worth $29,000 after purchasing an additional 510 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of AtriCure by 114.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,597 shares of the medical device company’s stock worth $48,000 after purchasing an additional 853 shares during the last quarter. Captrust Financial Advisors bought a new stake in shares of AtriCure in the second quarter worth about $134,000. Acadian Asset Management LLC increased its holdings in shares of AtriCure by 100.8% in the second quarter. Acadian Asset Management LLC now owns 4,623 shares of the medical device company’s stock worth $138,000 after purchasing an additional 2,321 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in AtriCure in the first quarter worth about $145,000. 88.85% of the stock is currently owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

See Also: What factors cause inflation to rise?

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.